Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-blind, phase III placebo-controlled study for PAH treatment

Next Previous
Trial Profile

A multi-center, randomized, double-blind, phase III placebo-controlled study for PAH treatment

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IKT 001PRO (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPROVE-PAH

Most Recent Events

  • 20 Nov 2025 According to a Inhibikase Therapeutics media, given the Company was well-advanced in initiating the previous Phase 2b study design, the Company expects to initiate IMPROVE-PAH in the first quarter of 2026, with this study expected to be conducted in up to approximately 180 sites around the world.
  • 20 Nov 2025 According to a Inhibikase Therapeutics media, the Company submitted a Type C Meeting request to the U.S. Food & Drug Administration ("FDA") to, among other things, obtain feedback on an immediate transition to a pivotal Phase 3 study design.
  • 14 Nov 2025 According to a Inhibikase Therapeutics media, The Company has been actively working with potential sites expects to initiate IMPROVE-PAH in the fourth quarter of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top